Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CNS Pharmaceuticals, Inc. - Common Stock
(NQ:
CNSP
)
5.130
-0.250 (-4.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about CNS Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data Shows Increase in Mortality Among Patients with Malignant Brain Tumors
December 12, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin
December 12, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Preliminary Results from Berubicin Trial
December 08, 2022
Via
Investor Brand Network
Research Recommends Reduction of Pediatric Brain Irradiation During Cancer Treatment
December 05, 2022
Via
Investor Brand Network
Four Facts You Need to Know About Brain Cancer
November 29, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in ‘Ask the CEO’ Event
December 05, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Pricing for Public Offering
December 01, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) 1-for-30 Reverse Stock Split Now in Place
November 29, 2022
Via
Investor Brand Network
European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment
November 28, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment
November 23, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial
November 22, 2022
Via
Investor Brand Network
Implanted Pump Holds Promise in Treating Brain Cancer
November 21, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO Participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run Following European Clinical Trial Site Activations
November 16, 2022
Via
Investor Brand Network
Researchers Turn to AI for Insights on Treating Brain Tumors
November 15, 2022
Via
Investor Brand Network
Topics
Artificial Intelligence
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2022 Financial Numbers, Corporate Update
November 15, 2022
Via
Investor Brand Network
Scientists Look for Ways to Disable Sugar Molecule That Fuels Cancer Persistence
November 14, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin
November 14, 2022
Via
Investor Brand Network
Research Finds New Therapy Path for Brain Cancer
November 10, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Strong Cash Position as It Continues Drug Development Program Pursuing Treatment for GBM
November 10, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Targeted ‘Finish Line Is Within Sight’ as It Pursues Potential GBM Treatment
November 07, 2022
Via
Investor Brand Network
New Brain Cancer Clinical Trial Platform Launched in Australia
November 07, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Patient in Global Berubicin Trial Evaluating GBM Treatment
November 02, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM
October 31, 2022
Via
Investor Brand Network
Researchers Discover New Way to Noninvasively Monitor Immune Cells Inside Tumors
October 27, 2022
Via
Investor Brand Network
Patient Plays Sax During Lengthy Surgery to Remove Brain Tumor
October 20, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Anticipating 2023 IND Application for Secondary Portfolio Candidate
October 17, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Executes on Several Clinical, Operational Advancements in Pursuit of GBM Treatment
October 14, 2022
Via
Investor Brand Network
Researchers Uncover Vital Clues on Drivers Behind Growth, Size of Brain Tumors
October 13, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Participate in Breakthrough for Brain Tumors(R) 5K Run
October 10, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Advancement of Berubicin Clinical Trial Featured in Syndicated Broadcast
October 07, 2022
Via
Investor Brand Network
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.